Stay updated on Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The clinical trial record describes a phase II study combining pembrolizumab with postoperative radiotherapy for high-risk cutaneous squamous cell cancer of the head and neck. It includes the study design, eligibility criteria, outcome measures, and record details.
    Difference
    48%
    Check dated 2026-11-08T04:22:29.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T01:40:36.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    An NIH banner announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) across federal agency content and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T01:42:17.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T01:28:30.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T01:56:57.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.7.0 was added. A number of study document attachments were removed from the Study Documents section, including the Informed Consent Form (2019-12-04) and the Study Protocol/Statistical Analysis Plan PDFs.
    Difference
    18%
    Check dated 2026-09-20T00:41:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.